Publications

  1. Cruz-Collazo A, Ruiz-Calderon JF, Picon H, Borrero-Garcia LD, Lopez I, Castillo-Pichardo L, Maldonado MDM, Duconge J, Medina JI, Bayro MJ, Hernandez-O'Farrill E, Vlaar CP, Dharmawardhane S. Efficacy of Rac and Cdc42 inhibitor MBQ-167 in triple negative breast cancer. Mol Cancer Ther. 2021 Oct 4:molcanther.0348.2021. doi: 10.1158/1535-7163.MCT-21-0348. Epub ahead of print. PMID: 34607932.
     
  2. Duconge J, Santiago E, Hernandez-Suarez DF, Moneró M, López-Reyes A, Rosario M, Renta JY, González P, Ileana Fernández-Morales L, Antonio Vélez-Figueroa L, Arce O, Marín-Maldonado F, Nuñez H, Melin K, Scott SA, Ruaño G. Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach. Clin Transl Sci. 2021 Aug 20. doi: 10.1111/cts.13124. Epub ahead of print. PMID: 34415683.
     
  3. Valdés-Fernández BN, Duconge J, Espino AM, Ruaño G. Personalized health and the coronavirus vaccines-Do individual genetics matter? Bioessays. 2021 Sep;43(9):e2100087. doi: 10.1002/bies.202100087. Epub 2021 Jul 26. PMID: 34309055; PMCID: PMC8390434.
     
  4. Sangkuhl K, Claudio-Campos K, Cavallari LH, Agundez JAG, Whirl-Carrillo M, Duconge J, Del Tredici AL, Wadelius M, Rodrigues Botton M, Woodahl EL, Scott SA, Klein TE, Pratt VM, Daly AK, Gaedigk A. PharmVar GeneFocus: CYP2C9. Clin Pharmacol Ther. 2021 Sep;110(3):662-676. doi: 10.1002/cpt.2333. Epub 2021 Jul 12. PMID: 34109627.
     
  5. Morales-Borges RH, Gonzalez MJ, Duconge J, Minich DM. N-Acetyl Cysteine and Glutathione in Health and Cancer-Pharmacogenomics, Research, and Clinical Practice: Hypothesis and Review. Altern Ther Health Med. 2020 Dec 29:AT6336. Epub ahead of print. PMID: 33373322.
     
  6. Santiago D, Mangas-Sanjuan V, Melin K, Duconge J, Zhao W, Venkataramanan R. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics. 2020 Dec 18;12(12):1226. doi: 10.3390/pharmaceutics12121226. PMID: 33352843; PMCID: PMC7766849.
     
  7. Asiimwe IG, Zhang EJ, Osanlou R, Krause A, Dillon C, Suarez-Kurtz G, Zhang H, Perini JA, Renta JY, Duconge J, Cavallari LH, Marcatto LR, Beasly MT, Perera MA, Limdi NA, Santos PCJL, Kimmel SE, Lubitz SA, Scott SA, Kawai VK, Jorgensen AL, Pirmohamed M. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis. Clin Pharmacol Ther. 2020 Jun;107(6):1420-1433. doi: 10.1002/cpt.1755. Epub 2020 Jan 28. PMID: 31869433; PMCID: PMC7217737.
     
  8. Roche-Lima A, Roman-Santiago A, Feliu-Maldonado R, Rodriguez-Maldonado J, Nieves-Rodriguez BG, Carrasquillo-Carrion K, Ramos CM, da Luz Sant'Ana I, Massey SE, Duconge J. Machine Learning Algorithm for Predicting Warfarin Dose in Caribbean Hispanics Using Pharmacogenetic Data. Front Pharmacol. 2020 Jan 22;10:1550. doi: 10.3389/fphar.2019.01550. PMID: 32038238; PMCID: PMC6987072.
     
  9. Botton MR, Whirl-Carrillo M, Del Tredici AL, Sangkuhl K, Cavallari LH, Agúndez JAG, Duconge J, Lee MTM, Woodahl EL, Claudio-Campos K, Daly AK, Klein TE, Pratt VM, Scott SA, Gaedigk A. PharmVar GeneFocus: CYP2C19. Clin Pharmacol Ther. 2021 Feb;109(2):352-366. doi: 10.1002/cpt.1973. Epub 2020 Jul 22. PMID: 32602114; PMCID: PMC7769975.
     
  10. Hernandez-Suarez DF, Melin K, Marin-Maldonado F, Nunez HJ, Gonzalez AF, Gonzalez-Sepulveda L, Rivas-Tumanyan S, Naik H, Ruaño G, Scott SA, Duconge J. Implementing a pharmacogenetic-driven algorithm to guide dual antiplatelet therapy (DAPT) in Caribbean Hispanics: protocol for a non-randomised clinical trial. BMJ Open. 2020 Aug 6;10(8):e038936. doi: 10.1136/bmjopen-2020-038936. PMID: 32764090; PMCID: PMC7412606.
     
  11. Reyes-González S, de Las Barreras C, Reynaldo G, Rodríguez-Vera L, Vlaar C, Mejias VL, Monbaliu JM, Stelzer T, Mangas V, Duconge J. Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans. Drug Metab Pers Ther. 2020 Aug 19:/j/dmdi.ahead-of-print/dmdi-2020-0135/dmdi-2020-0135.xml. doi: 10.1515/dmdi-2020-0135. Epub ahead of print. PMID: 32809952; PMCID: PMC7892629.
     
  12. El Rouby N, Rodrigues Marcatto L, Claudio K, Camargo Tavares L, Steiner H, Botton MR, Lubitz SA, Fallon EN, Yee K, Kaye J, Scott SA, Karnes J, Caleb Junior de Lima Santos P, Duconge J, Cavallari LH. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos. Clin Transl Sci. 2021 Jan;14(1):268-276. doi: 10.1111/cts.12854. Epub 2020 Sep 8. PMID: 32860733; PMCID: PMC7877858.
     
  13. Rodríguez-Escudero I, Cedeño JA, Rodríguez-Nazario I, Reynaldo-Fernández G, Rodríguez-Vera L, Morales N, Jiménez-Vélez B, Ruaño G, Duconge J. Assessment of the clinical utility of pharmacogenetic guidance in a comprehensive medication management service. J Am Coll Clin Pharm. 2020 Sep;3(6):1028-1037. doi: 10.1002/jac5.1250. Epub 2020 May 2. PMID: 32964197; PMCID: PMC7505210.
     
  14. Reig-López J, Maldonado MDM, Merino-Sanjuan M, Cruz-Collazo AM, Ruiz- Calderón JF, Mangas-Sanjuán V, Dharmawardhane S, Duconge J. Physiologically- Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice. Pharmaceutics. 2020 Oct 15;12(10):975. doi: 10.3390/pharmaceutics12100975. PMID: 33076517; PMCID: PMC7602742.
     
  15. Seguí HA, Melin K, Quiñones DS, Duconge J. A review of the pharmacogenomics of buprenorphine for the treatment of opioid use disorder. J Transl Genet Genom. 2020;4:263-277. doi: 10.20517/jtgg.2020.35. Epub 2020 Jul 30. PMID: 33274315; PMCID: PMC7709797.
     
  16. Santiago D, Mangas-Sanjuan V, Melin K, Duconge J, Zhao W, Venkataramanan R. Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico. Pharmaceutics. 2020 Dec 18;12(12):1226. doi: 10.3390/pharmaceutics12121226. PMID: 33352843; PMCID: PMC7766849.
     
  17. Morales-Borges RH, Gonzalez MJ, Duconge J, Minich DM. N-Acetyl Cysteine and Glutathione in Health and Cancer-Pharmacogenomics, Research, and Clinical Practice: Hypothesis and Review. Altern Ther Health Med. 2020 Dec 29:AT6336. Epub ahead of print. PMID: 33373322.
     
  18. De la Rosa MVG, Santiago R, Romero JM, Duconge J, Monbaliu JC, López-Mejías V, Stelzer T. Solubility Determination and Correlation of Warfarin Sodium 2-Propanol Solvate in Pure, Binary, and Ternary Solvent Mixtures. J Chem Eng Data. 2019 Apr 11;64(4):1399-1413. doi: 10.1021/acs.jced.8b00977. Epub 2019 Apr 1. PMID: 32536719; PMCID: PMC7291792.
     
  19. Graydon JS, Claudio K, Baker S, Kocherla M, Ferreira M, Roche-Lima A, Rodríguez-Maldonado J, Duconge J, Ruaño G. Ethnogeographic prevalence and implications of the 677C>T and 1298A>C MTHFR polymorphisms in US primary care populations. Biomark Med. 2019 Jun;13(8):649-661. doi: 10.2217/bmm-2018-0392. Epub 2019 Jun 3. PMID: 31157538; PMCID: PMC6630484.
     
  20. Claudio-Campos K, Moneró-Paredes M, Hernández E, Renta J, Duconge J. Low- frequency variants at the CYP2C9 locus among Puerto Rican patients on warfarin: in silico predictions of functionality and conservation. Pharmacogenomics. 2019 Aug;20(12):891-902. doi: 10.2217/pgs-2019-0051. PMID: 31453773; PMCID: PMC6739902.
     
  21. Maldonado MDM, Rosado-González G, Bloom J, Duconge J, Ruiz-Calderón JF, Hernández-O'Farrill E, Vlaar C, Rodríguez-Orengo JF, Dharmawardhane S. Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography-Tandem Mass Spectrometry. ACS Omega. 2019 Oct 23;4(19):17981-17989. doi: 10.1021/acsomega.9b01641. PMID: 31720502; PMCID: PMC6843717.
     
  22. Claudio-Campos KI, González-Santiago P, Renta JY, Rodríguez J, Carrasquillo K, Gaedigk A, Roche A, Ducongé J. CYP2C9*61, a rare missense variant identified in a Puerto Rican patient with low warfarin dose requirements. Pharmacogenomics. 2019 Jan;20(1):3-8. doi: 10.2217/pgs-2018-0143. 
     
  23.  Kyle Melin, Jee-Young Moo, Qibin Q, Dagmar F Hernandez-Suarez, Jorge Duconge, Simin Hua, Sara Gonzalez, Donglin Zeng, Robert C Kaplan. Prevalence of pharmacogenomic variants affecting the efficacy of clopidogrel therapy in the Hispanic Community Health Study/Study of Latinos cohort. Pharmacogenomics. 2018. doi: 10.2217/pgs-2018-0148.
     
  24. Michael J Gonzalez; Thomas Seyfried; Garth L. Nicolson; Barry J Barclay; Jaime Matta; Alex Vasquez; Dominic D'Agostino; Jose Olalde; Jorge Duconge; Ron Hunninghake; Miguel J Berdiel; Amanda Cintrón. Mitochondrial Correction: A New Therapeutic Paradigm for Cancer and Degenerative Diseases. Journal of Orthomolecular Medicine 2018; Aug Vol. 33 (4):1-20.
     
  25. Michael J Gonzalez, Miguel J Berdiel, Jorge Duconge, Thomas E Levy, Ines M Alfaro, Raul Morales-Borges, Victor Marcial-Vega, Jose Olalde. High Dose Intravenous Vitamin C and Influenza: A Case Report. Journal of Orthomolecular Medicine 2018; June Vol. 33 (3):1-3.
     
  26. Dagmar F Hernandez-Suarez, Mariana R Botton, Stuart A Scott, Matthew I Tomey, Mario J Garcia, Jose Wiley, Pedro A Villablanca, Kyle Melin, Angel Lopez-Candales, Jessicca Y Renta, Jorge Duconge. Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. Pharmacogenomics and Personalized Medicine 2018:11 95-106. PMCID: PMC5996853 https://www.dovepress.com/articles.php?article_id=38745.
     
  27. Jorge Duconge, Gualberto Ruaño. Preventing the Exacerbation of Health Disparities by Iatrogenic Pharmacogenomics Applications: Lessons from Warfarin. Pharmacogenomics 2018, Jun 14. doi: 10.2217/pgs-2018-0055.
     
  28. Hernandez-Suarez DF, Tomassini-Fernandini JC, Cuevas A, Rosario-Berrios AN, Nuñez-Medina HJ, Padilla-Arroyo D, Rivera N, Liriano J, Vega-Roman RK, Renta JY, Melin K, Duconge J. Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program. Int. J. Environ. Res. Public Health 2018; 15(6): 1115; https://doi.org/10.3390/ijerph15061115 Proceedings of Research Centers at Minority Institutions (RCMI) Translational Science 2017 Conference. PMCID: PMC6025039.
     
  29. Reynaldo G, Rodríguez L, Menéndez R, Solazabal J, Amaro D, Becquer MA, Colom Y, Gil H, Polo JC, Castañeda G, Jiménez-Vélez B, Duconge J, Fernández-Sánchez EM. A comparative pharmacokinetic and pharmacodynamic study of two novel Cuban PEGylated rHuEPO versus MIRCERA® and ior®EPOCIM. Journal of Pharmacy & Pharmacognosy Research 2018; 6 (3): 179-190. ISSN 0719-4250; http://jppres.com/jppres/pdf/vol6/jppres17.342_6.3.179.pdf  PMCID: PMC6364991.
     
  30. Hernandez-Suarez DF, Nuñez-Medina H, Scott SA, Lopez-Candales A, Wiley JM, Garcia MJ, Melin K, Nieves-Borrero K, Rodriguez-Ruiz C, Marshall L, Duconge J. Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. Drug Metab Pers Ther. 2018 Mar 28; 33(1):49-55. doi: 10.1515/dmpt-2017-0032. PMCID: PMC5840033.
     
  31. Crespo-Bujosa HB, Gonzalez MJ, Duconge J, González MJ, Rodriguez JR (2017) Nutrient Depletion-Induced Neuro-Chemical Disorder (Brain Hunger) as the Basis of Psychopathology and Aggressive Behavior, J Orthomol Med 2017; 32(5): Open access. https://www.isom.ca/article/nutrient-depletion-induced-neuro-chemical-disorder-brain-hunger-basis-psychopathology-aggressive-behavior/ 
     
  32. Martes-Martinez C, Mendez-Sepúlveda C, Millan-Molina J, French-Kim M, Marín-Centeno H, Rivera-Miranda G, Hernández-Muñoz JJ, Duconge-Soler J. Cost-Utility of Warfarin Genotyping in the VACHS affiliated Anticoagulation Clinic in Puerto Rico. PR Health Sci Journal 2017; 36(3):165-172. PMCID: PMC5993426.
     
  33. Gonzalez MJ, Duconge J. Tumor Growth dynamics: Dietary fish oil induced inhibition of human breast carcinoma growth, a phenomenon of reduced cellular DNA synthesis or increased cell loss? J Neoplasms 2017 (in press)
     
  34. Keishla M. García, Karla M. Flores, Adriana Falcón, Charlynne De Jesus, Loida Del Rio, Laura C. Rivera, Michelle Marquez, Santos Ortiz, Gretchen Sandoval, Alejandro Ruiz, Fabiola Rodriguez, Frances Gonzalez, Kenneth Cintron, Miguel J. Berdiel, Jorge Duconge, Maricelly Santiago, Ines Alfaro and Michael J. Gonzalez. Perioperative Effects of Surgery, Anesthesia and Analgesics Associated with Cancer Progression: A Review. Journal of Cancer Research Updates, 2018, 7, 1-20.
     
  35. Michael J. Gonzalez, Jose Olalde, Jose R. Rodriguez, Diana Rodriguez, Jorge Duconge. Metabolic Correction and Physiologic Modulation as the Unifying Theory of the Healthy State: The Orthomolecular, Systemic and Functional Approach to Physiologic Optimization. Journal of Orthomolecular Medicine 2018, Vol. 33 (1):15-17.
     
  36. Miranda-Massari JR, González MJ, Jiménez Ramírez FJ, Duconge J, Marín H, et al. Metabolic Correction As a Proposed Approach for Reduction of Complications and. Costs of Diabetes Care in Puerto Rico. Endocrinol Diabetes Open Access. 2018; 1(1):103.
     
  37. Jarline Encarnación-Medina, Rosa I. Rodríguez-Cotto, Joseph Bloom-Oquendo, Mario G. Ortiz-Martínez, Jorge Duconge and Braulio D. Jiménez-Vélez. Selective ATP-Binding Cassette Subfamily C gene expression and pro inflammatory Mediators released by BEAS-2B after PM2.5, Budesonide and a Co-Treated Exposures. Mediators Inflamm. 2017:6827194. doi: 10.1155/2017/6827194. vol. 2017, Article ID 6827194. PMCID: PMC5576432.
     
  38. Hernandez-Suarez DF, Scott S, Tomey MI, Melin K, Lopez-Candales A, Buckley C, Duconge J. Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics Ther Adv Cardiovasc Dis. 2017 Sep;11(9):235-241. doi: 10.1177/1753944717718718. PMCID: PMC5555769.
     
  39. Claudio-Campos K, Labastida A, Ramos A, Gaedigk A, Renta-Torres J, Padilla D, Rivera-Miranda G, Scott SA, Ruano G, Cadilla C, Duconge-Soler J. Warfarin Anticoagulation Therapy in Caribbean Hispanics of Puerto Rico: A candidate gene association study. Frontiers in Pharmacology, section Pharmacogenetics & Pharmacogenomics. 2017; 8:347. doi: 10.3389/fphar.2017.00347 PMCID: PMC5461284 https://doi.org/10.3389/fphar.2017.00347.
     
  40. Nina A. Mikirova, Joseph J. Casciari, Michael J. Gonzalez, Jorge R. Miranda-Massari, Neil H. Riordan and Jorge Duconge. Bioenergetics of Human Cancer Cells and Normal Cells during Proliferation and Differentiation. Canc Therapy & Oncol Int J 2017; 3(5): CTOIJ.MS.ID.555623.
     
  41. Duconge J, Hernandez-Suarez DF. Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting. Curr Clin Pharmacol. 2017; 12(1):11-17. doi: 10.2174/1574884712666170227154654. PMCID: PMC5478430.
     
  42. Francisco J. Jiménez-Ramírez, Liza M. Castro, Clarymar Ortiz, Jennifer Concepción, Jessicca Y. Renta, Raul H. Morales-Borges, Jorge R. Miranda-Massari and Jorge Duconge. Role of Treatment-modifying MTHFR 677C>T and 1298A>C Polymorphisms in Metformin-treated Puerto Rican Patients with Type-2 Diabetes Mellitus and Peripheral Neuropathy. Drug Metabol Personal Ther. 2017; DOI 10.1515/dmpt-2016-0039. PMCID: PMC5436794.
     
  43. Martínez R, Carpio Y, Arenal A, Lugo JM, Morales R, Martín L, Rodríguez RF, Acosta J, Morales A, Duconge J and Estrada MP. Significant improvement of shrimp growth performance by growth hormone-releasing peptide-6 immersion treatments. Aquaculture Res. 2017; doi:10.1111/are.13286.
     
  44. Pericchi LR, Duconge J, Miranda-Massari JR, Gonzalez MJ, Nieves M, Torres D, Hickey S. Simulation-Based Design of Phase I Clinical Trial of Intravenous Vitamin C Treatment. Int J Cancer Res Ther, 2017; 1(1):1-4.
     
  45. González MJ, Berdiel MJ, Miranda-Massari JR, López D, Duconge J, Rodriguez JL, Adrover P. High dose intravenous vitamin C and metastatic pancreatic cancer: Two cases. Integr Cancer Sci Therap 2016; 3(6):1-2 doi: 10.15761/ICST.1000219.
     
  46. Gonzalez MJ, Miranda-Massari JR, Duconge J. The Bio-Energetic Theory of Carcinogenesis: The Origin of Cancer Revisited. J Orthomol Med 2016; 31(2):84-89.
     
  47. Jorge R. Miranda-Massari, José R. Rodríguez-Gómez, Michael J. González, Carlos Cidre, Jorge Duconge, Heriberto Marin, Kazuko Grace, Howard L. McLeod. Metabolic Correction in Patients Sample with Diabetes: Clinical Outcomes and Costs Reductions. International Journal of Diabetes Research 2016, 5(5): 92-101. doi: 10.5923/j.diabetes.20160505.02.
     
  48. De Jesus-Ramos C, Garcia K, Berdiel MJ, Miranda-Massari JR, Duconge J, Gonzalez MJ. Huntington Disease Management with Metabolic Correction: Preliminary Findings. Journal of Orthomolecular Medicine 2016 Dec.; 31(2):91-96.
     
  49. Michelle D. Adams, Michael J. Gonzalez, Jorge R. Miranda-Massari, Jorge Duconge, Jose R. Rodriguez-Gomez, Miguel J. Berdiel, Kenneth Cintron. An Integrative Approach to Hypertension: A Comprehensive Review of Antihypertensive Nutrients and Botanicals. Journal of Restorative Medicine 2016; 5: page 57-73. doi: 10.14200/jrm.2016.5.0104.
     
  50. Pedro A. Adrover-López, Michael J. Gonzalez, Jorge R. Miranda-Massari, Jorge Duconge, Miguel J. Berdiel. Inflammatory Sequelae after Chikungunya Virus Infection: Proposed Nutritional Treatment. Journal of Restorative Medicine 2016; 5: page 39-45. doi: 10.14200/jrm.2016.5.0103.
     
  51. Dagmar F. Hernandez-Suarez, Karla Claudio-Campos, Javier E. Mirabal-Arroyo, Bianca A. Torres-Hernández, Angel López-Candales, Kyle Melin, Jorge Duconge. Potential of a Pharmacogenetic-Guided Algorithm to Predict Optimal Warfarin Dosing in a High-Risk Hispanic Patient: Role of a Novel NQO1*2 Polymorphism. J Investig Med High Impact Case Rep. 2016 Dec 1; 4(4):2324709616682049. DOI: 10.1177/2324709616682049. PMCID: PMC5298566.
     
  52. Carolina Céspedes-Garro, María-Eugenia G. Naranjo, Fernanda Rodrigues-Soares, Adrián LLerena, Jorge Duconge, Lazara Karelia Montané-Jaime, Hilda Roblejo, Humberto Fariñas, María de los Angeles Campos, Ronald Ramírez, Víctor Serrano, Carmen I Villagrán and Eva M Peñas-Lledó. Pharmacogenetic research activity in Central America and the Caribbean: A systematic review. Pharmacogenomics 2016 Nov; 17(15): 1707-1724. doi 10.2217/pgs-2016-0053. PMCID: PMC5558513.
     
  53. Duconge J, Ruaño G. Admixture and Ethno-specific Alleles: missing links for global pharmacogenomics. Pharmacogenomics 2016 Sep; 17(14):1479-82. doi: 10.2217/pgs-2016-0115. PMID: 27537834.
     
  54. Michael J. Gonzalez, Jorge R Miranda-Massari, Miguel J. Berdiel, Jorge Duconge, Joshua L. Rodríguez, Pedro A. Adrover-López. High Dose Intravenous Vitamin C Treatment for Zika Fever. J Orthomol Med 2016; 31(1):
     
  55. Gonzalez MJ, Miranda-Massari JR, Duconge J, Berdiel MJ. Increasing the Effectiveness of Intravenous Vitamin C as an Anticancer Agent. [Educational Article]. J Orthomol Med 2015; 30(1): 1-5.
     
  56. Michael J. González, Miguel J. Berdiel, Jorge R. Miranda- Massari, Desireé López, Joshua L. Rodríguez-López, Pedro A. Adrover-López, Jorge Duconge. High dose intravenous vitamin C treatment in a patient with lung cancer: A case report. Clin Case Rep Rev, 2016; June, Vol. 2(6): 454-455 doi: 10.15761/CCRR.1000243.
     
  57. Miranda-Massari JR, Gonzalez MJ, Duconge J, Berdiel MJ, Alfaro I, Kazuko G. Editorial: Metabolic correction therapy: Changing the healthcare management paradigm. Integr Food Nutr Metab, 2016; Vol. 3(2): 281-282. doi: 10.15761/IFNM.1000142.
     
  58. Duconge J, Ramos AS, Claudio K, Rivera G, Bermudez-Bosch L, Renta JY, Cadilla CL, Cruz I, Feliu JF, Vergara C, Ruaño G. A Novel Admixture-based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PLoS ONE 2016; 11(1): e0145480. doi:10.1371/journal.pone.0145480. journals.plos.org/plosone/article?id=info:doi/10.1371/journal.pone.0145480. PMCID: PMC4706412.
     
  59. Adams MA, Gonzalez MJ, Miranda-Massari JR, Duconge J, Gonzalez MJ, Rodríguez-Gómez JR, Berdiel MJ, Cintron K. New Views on Saturated Fat, Sugar, and the Cardiovascular Disease Epidemic. International Journal of Human Nutrition and Functional Medicine Open Access 2015; Dec / 2016 Jan www.IntJHumNutrFunctMed.org.
     
  60. Claudio-Campos K, Orengo-Mercado C, Renta JY, Peguero M, Garcia R, Hernández G, Corey S, Cadilla CL, Duconge J. Pharmacogenetics of healthy volunteers in Puerto Rico. Drug Metabol Personal Ther. 2015 Dec 1; 30(4): 239-249. pii: /j/dmdi.ahead-of-print/dmpt-2015-0021/dmpt-2015-0021.xml
     
  61. doi: 10.1515/dmpt-2015-0021. PMCID: PMC4768757.
     
  62. Duconge J, Cadilla CL, Seip RL, Ruaño G. Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials. PR Health Sci J. 2015 Sep; 34(3):175-7. PMCID: PMC4770896.
     
  63. Miranda-Massari JR, González MJ, Rodriguez-Gomez JR, Duconge J, Allende-Vigo MZ, Jiménez Ramirez FJ, Cintrón K, Ricart C, Zaragoza-Urdaz R, Berdiel MJ, Vázquez A. Metabolic correction: a biochemical option against diseases. Bol Asoc Med PR. 2015 Apr-Jun; 107(2):60-6. Review. Spanish. PMID: 26434086.
     
  64. Miranda-Massari JR, Gonzalez MJ, Fernando AS, Cidre C, Paz IM, Charvel J, Martínez V, Duconge J, Aponte A, Ricart CM. Metabolic Correction as a tool to improve diabetes type 2 management. Bol Asoc Med PR. 2015 Apr-Jun; 107(2):54-9. PMID: 26434085.
     
  65. Duconge J, Ruaño G. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation. Pharmacogenomics 2015; 16(15):1685-8. doi: 10.2217/pgs.15.123. PMID: 26431456.
     
  66. Gonzalez MJ, Miranda-Massari JR, Duconge J, Berdiel MJ. Increasing the Effectiveness of Intravenous Vitamin C as an Anticancer Agent. [Educational Article]. J Orthomol Med 2015; 30(1): 1-5.
     
  67. González MJ, Miranda-Massari JR, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Cintrón K, Rodríguez-Gómez JR, Rosario G, Ricart C, Santiago-Cornier JA, Zaragoza-Urdaz R, Vázquez A, Hickey S, Berdiel MJ, Riordan N, Ichim T, Santiago O, Alvarado G, Vora P. Metabolic Correction: A Functional Biochemical Mechanism against Disease Part 1: Concept and Historical Background. PR Health Sci J 2015;34:3-8.
     
  68. Miranda-Massari JR, González MJ, Duconge J, Allende-Vigo MZ, Jiménez-Ramírez FJ, Hickey S, Vázquez A, Berdiel MJ, Cintrón K, Rodríguez-Gómez JR, Metabolic Correction: A Functional Biochemical Mechanism against Disease Part 2: Mechanisms and Benefits. PR Health Sci J 2015;34:9-13.
     
  69. Humphries-Bickley T, Castillo-Pichardo L, Corujo-Carro F, Duconge J, Hernandez-O'Farrill E, Vlaar C, Rodriguez-Orengo JF, Cubano L, Dharmawardhane S. Pharmacokinetics of Rac inhibitor EHop-016 in mice by ultra-performance liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jan 2; 981-982C:19-26. PMCID: PMC4306626.
     
  70. Gonzalez MJ, Miranda-Massari JR, Duconge J, Rodríguez JR, Cintron K, Berdiel MJ, Rodríguez JW. Nutrigenomics, Metabolic Correction and Disease: The Restoration of Metabolism as a Regenerative Medicine Perspective. Journal of Restorative Medicine 2015; 4: 74-82. doi 10.14200/jrm.2014.4.0109.
     
  71. Duconge J. Population Heterogeneity and Genomic Admixture: Relevance for Global Pharmacogenetics. J Pharmacogenom Pharmacoproteomics 2014, 5:5 e141. doi:10.4172/2153-0645.1000e141.
     
  72. Claudio-Campos K, Duconge J, Cadilla CL, Ruaño G. Pharmacogenetics of drug-metabolizing enzymes in US Hispanics. Drug Metabol Personal Ther. 2015 Jun; 30(2):87-105. doi: 10.1515/dmdi-2014-0023. PMCID: PMC4447600.
     
  73. Gonzalez MJ, Miranda-Massari JR, Berdiel MJ, Duconge J, Rodríguez-López JL, Hunninghake R, Cobas-Rosario VJ. High Dose Intravenous Vitamin C and Chikungunya Fever: A Case Report. J Orthomol Med. 2014; 29(4):154-156. PMCID:  PMC4335641.
     
  74. Zeviar DD, Gonzalez MJ, Miranda-Massari JR, Duconge J, Mikirova N. The Role of Mitochondria in Cancer and other Chronic Diseases. J Orthomol Med. 2014; 29(4):157-166.
     
  75. Fernandez-Sanchez EM, Duconge J. The History of Pharmacokinetics in Cuba: Role of Universities. Journal of Pharmacy and Pharmacology 2014; 2(8): 453-469.
     
  76. Valentin I, Rivera G, Nieves-Plaza M, Cruz I, Renta JY, Cadilla CL, Feliu JF, Seip RL, Ruaño G, Duconge J. Pharmacogenetic Association Study of Warfarin Safety Endpoints in Caribbean Hispanics. PR Health Sci. Journal 2014; 33:97-104. PMCID: PMC4196861.
     
  77. Duconge J, Cadilla CL. CYP2D6's functional status associated with the length of hospitalization stay in psychiatric patients: a twist in the tale or evidence that matters? Biomark Med. 2013 Dec; 7(6):913-4. PMCID: PMC4109677.
     
  78. Gonzalez MJ, Miranda-Massari JR, Duconge J, Arroyo JP. Chronic Diseases as Inborn Errors of Metabolism: The Metabolic Correction Therapy Approach. International Journal of Human Nutrition and Functional Medicine Open Access 2014:2(1);2 http://intjhumnutrfunctmed.org/publications/index.html.
     
  79. Orengo-Mercado C, Nieves B, Lopez L, Valles-Ortiz N, Renta Y, Santiago-Borrero PJ, Cadilla CL and Duconge J. Frequencies of Functional Polymorphisms in Three Pharmacokinetic Genes of Clinical Interest within the Admixed Puerto Rican Population. J Pharmacogenom Pharmacoproteomics 2013; (4)1:113. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769800/ . PMCID: PMC3769800.
     
  80. Ramos AS, Seip R, Rivera G, Felici M, Alejandro-Cowan Y, Garcia R, Kocherla M, Renta J, Cruz I, Feliu JF, Cadilla CL, Gorowski K, Vergara C, Ruaño G, and Duconge J. Development of a Pharmacogenetic-guided Warfarin Dosing Algorithm for Puerto Rican Patients. Pharmacogenomics 2012; 13(16): 1937-50. doi: 10.2217/pgs.12.171. PMCID: PMC3538136 [recipient of the ASHP Foundation Literature Awards: Student Research Award]
     
  81. Duconge J, Ruaño G. 'Generic to genetic' transition in cardiovascular and neuropsychiatric drugs: opportunity for personalized medicine. Pharmacogenomics 2012; 13(10): 1097-1100. PMCID: PMC3505752.
     
  82. González MJ, Miranda Massari JR, Duconge J, Riordan NH, Ichim T, Quintero-Del-Rio AI, Ortiz N. The Bio-energetic Theory of Carcinogenesis. Med Hypotheses. 2012; 79: 433-39. PMID: 22809841. 
     
  83. González MJ, Miranda-Massari JR, Duconge J, Riordan NH, IchimT. Schedule Dependence in Cancer Therapy: Vitamin C and the Systemic Saturation. Journal of Orthomolecular Medicine. 2012; 27:9-12 PMCID: PMC4031610.
     
  84. Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, Ruaño G, and Duconge J. Prediction of Warfarin Dose Reductions in Puerto Rican Patients based on Combinatorial CYP2C9 and VKORC1 Genotypes. The Annals of Pharmacotherapy. 2012; 46(2): 208-18. PMCID: PMC3378722.
     
  85. Miranda-Massari JR, Gonzalez MJ, Jimenez FJ, Allende-Vigo M, Duconge J. Metabolic Correction in the Management of Diabetic Peripheral Neuropathy: Improving Clinical Results beyond Symptom Control. Current Clinical Pharmacology 2011; 6(4):260-273. PMCID: PMC3682498.
     
  86. Riordan N, Rubin D, González MJ, Miranda-Massari JR, Alfaro I, Rodríguez JR, Ricart CM, Cintrón K, Valentin II, Duconge J. El Sistema Inmunológico y el Cáncer: Pueden las células dendríticas ser la clave? Medicina y Salud Publica 2011; Vol. XXVIII: 10-22.
     
  87. Duconge J, Ruaño G. Emerging Role of Admixture in the Pharmacogenetics of Puerto Rican Hispanics. J Pharmacogenom Pharmacoproteomics 2010; (4)1:101. PMCID: PMC3515058.
     
  88. Gonzalez MJ, Miranda-Massari J, Duconge J. Vitamin C and Cancer: What can we Conclude - 1,609 Patients and 33 Years Later: comment on the article by Dr. Cabanillas. Letter to the Editor. PR Health Sci J. 2010; 29(4): 410-411.
     
  89. Rodriguez-Velez R, Ortiz-Rivera OJ, Bower B, Gorowski K, Windemuth A, Villagra D, Kocherla M, Seip RL, D'Agostino D, Ruaño G, and Duconge J. Exposure to Non-Therapeutic INR in a High Risk Cardiovascular Patient: Potential Hazard Reduction with Genotype-Guided Warfarin (Coumadin®) Dosing. PR Health Sci J. 2010; 29(4): 402-408. PMCID: PMC3679530.
     
  90. Duconge J, Villagra D, Windemuth A, Cadilla CL, Kocherla M, Gorowski K, Bogaard K, Renta JY, Cruz IA, Mirabal S, Seip RL, Ruaño G. CYP2C9 and VKORC1 Genotypes in Puerto Ricans: A Case for Admixture-Matching in Clinical Pharmacogenetic Studies. Clinica Chimica Acta 2010; 411:1306-1311. PMCID: PMC2903218.
     
  91. Seip RL, Duconge J, Ruaño G. Implementing Genotype-guided Antithrombotic Therapy. Future Cardiology 2010; 6(3): 409-424. PMCID: PMC2903229.
     
  92. González MJ, Rosario-Pérez G, Guzman AM, Miranda-Massari JR, Duconge J, Lavergne J, Fernandez N, Ortiz N, Quintero del Rio AI, Mikirova N, Riordan NH, Ricart CM. Mitochondria, Energy and Cancer: The Relationship with Ascorbic Acid. Journal of Orthomolecular Medicine 2010; 25(1): 29-37. PMCID: PMC3615720.
     
  93.  Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta J, Paola Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G.  Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: Implications for Warfarin Management in Hispanics. Ethnicity & Disease 2009; 19(4): 390-395. PMCID: PMC2903231.
     
  94. Duconge J, Cadilla CL, Windemuth A, Kocherla M, Gorowski K, Seip RL, Bogaard K, Renta JY, Piovanetti P, D'Agostino D, Santiago-Borrero PJ, Ruaño G. For the patient. DNA makeup of Hispanic persons should be determined before warfarin prescription. Ethnicity & Disease 2009; 19(4):479-80.
     
  95. Ruaño G, Duconge J, Windemuth A, Cadilla CL, Kocherla M, Renta J, Seip R, Santiago-Borrero PJ. Physiogenomic Analysis of the Puerto Rican population. Pharmacogenomics 2009; 10(4):565-77. PMCID: PMC2846824.
     
  96. Bilbao-Díaz MF, Peña-Proenza Y, Gutiérrez-Bueno M, Cabrera Pérez MA, Duconge J, Linares GM, Fernández-Sánchez EM, Valdés YC. Inferable analysis related to promotion of the absorption potentialities from 1-O-alkyl glycerol family. Revista Cubana de Farmacia. 2009; 43(3):1-9.
     
  97. J Duconge, CL Cadilla, JY Renta, P Silen-Rivera, P Piovanetti, LM Castro-Rosario, S Monzon, G Rosas, L Velez, R Garcia-Berdecia, JA Guerra, PJ Santiago-Borrero. Prevalence of CYP2C19 Gene Polymorphisms in the Puerto Rican Population: A preliminary report. PR Health Sci J 2008; 27(4):357-8. PMCID: PMC2748933.
     
  98. J Duconge. Applying Organ Clearance Concepts in a Clinical Setting. Am J Pharm Edu 2008; 72 (5): 121. PMCID: PMC2630146.
     
  99. A LaSala; B Bower; A Windemuth, CM White; M Kocherla; R Seip; J Duconge; G Ruaño. Integrating Genomic Based Information into Clinical Warfarin (Coumadin) Management: An Illustrative Case Report. Connecticut Medicine 2008; 72(7): 83-87. PMCID: PMC3696193.
     
  100. G Ruano; Thompson PD; Villagra D; Bower B; Kocherla M; Yazdanpanah G; Seip R; Windemuth A; White CM; Duconge J; Holford TR; Wu AHB. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing. Personalized Medicine 2008; 5(3):225-232.
     
  101. J Duconge; N Merino; I Beausoleil; D Alvarez; L Rodriguez; E Fernandez-Sanchez; A Burt. Kinetics of Monoclonal Anti-epidermal growth factor receptor antibody (IOR EGF/r3)-induced apoptosis in human carcinoma bearing nude mice. PR Health Sciences Journal 2008; 27(1):35-41.
     
  102. J Duconge; JR Miranda-Massari; MJ Gonzalez; N Riordan; J Jackson; W Warnock. Pharmacokinetics of Vitamin C: Insights into the Oral and IV Administration of Ascorbate. PR Health Sciences Journal 2008; 27(1):7-19.
     
  103. J Duconge; JR Miranda-Massari; MJ Gonzalez; N Riordan. Schedule dependence in cancer therapy: what is the true scenario for vitamin C? Journal of Orthomolecular Medicine 2007; 22(1): 21-26.
     
  104. J Duconge, JR Miranda-Massari, MJ Gonzalez, N Riordan, H Riordan, J Casciari PR Taylor, K Alliston. Vitamin C Pharmacokinetics after Continuous IV Infusion in a Patient with Prostate Cancer. The Annals of Pharmacotherapy 2007; 41(6): 1082-3.
     
  105. Garcia-Santana MA, Duconge J, Sarmiento ME, Lanio-Ruiz ME, Becquer MA, Izquierdo L, Acosta-Dominguez A. Biodistribution of liposome-entrapped human gamma-globulin. Biopharmaceutics and Drug Disposition 2006; 27(6):275-283.
     
  106. Duconge J. The Case of Biotech-Derived Product Equivalence: Much Ado about Nothing? Current Clinical Pharmacology. 2006; 1(2): 147-156
     
  107. Duconge J, Rodríguez-Vera L, Valenzuela C, Álvarez D, Ramírez O, de la Luz-Hernández KR, Rabeza EY, Casaco A, Fernández-Sánchez E. Pharmacokinetic comparison of two recombinant human granulocyte colony-stimulating factors after subcutaneous administration in rabbits. European Journal of Pharmaceutics and Biopharmaceutics. 2005; 26, Oct., 61(3):142-8.
     
  108. Hernández F, García I, González CA, Valenzuela C, Soto R, Duconge J, Cervantes M, Blanco E, Rodríguez V, García Y, Bello I, Olivera L, López-Saura P. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharmaceutics and Drug Disposition. 2005; 26(4): 151-159.
     
  109. García I, González CA, Valenzuela C, Hernández F, Ferrero J, Soto R, Cervantes M, Duconge J, Correa A, Olivera L, López-Saura P. Bioequivalence of Two Recombinant Interferon alfa-2b Liquid Formulations in Healthy Male Volunteers. Drugs Research & Development. 2004; 5(5): 271-280.
     
  110. Duconge J, Prats PA, Valenzuela C, Aguilera A, Rojas I, Bécquer MA, Álvarez D, Estrada L, Alfonso-Ortiz S, Hardy E, García O, Fernández-Sánchez E. Topical Disposition of Two Strengths of a 125I-rhEGF Jelly in Rat Skin Wounds. Biopharmaceutics and Drug Disposition. 2004; 25(5): 193-201. 
     
  111. Duconge J, Fernández-Sánchez E. Un acercamiento al Sistema de Clasificación Biofarmacéutico: su impacto sobre la política reguladora cubana. Revista Cubana de Farmacia. 2004; 38(1): 335-345.
     
  112. Duconge J, Fernández-Sánchez E, Álvarez D. Interspecies Scaling of the Monoclonal Anti-EGF receptor ior EGF/r3 Antibody Disposition Using Allometric Paradigm: Is it Really Suitable? Biopharmaceutics and Drug Disposition. 2004; 25(4): 177-186.
     
  113. Duconge J, Castillo R, Crombet T, Alvarez D, Matheu J, Vecino G, Alonso K, Beausoleil I, Valenzuela C, Bécquer MA, Fernández-Sánchez E. Integrated pharmacokinetic-pharmacodynamic modeling and allometric scaling for optimizing the dosage regimen of the monoclonal ior EGF/r3 antibody. European Journal of Pharmaceutical Sciences. 2004; 21(2-3): 261-70. 
     
  114. Fernández-Sánchez E, Duconge J, Castillo R, García I, Beausoleil I, Macias A. Monoclonal anti-EGFR (ior egf/r3) antibody pharmacokinetic studies on nude mice I: A radio-receptor analysis applied to serum drug quantification. Journal of Pharmacy and Pharmacology. 2002; 54 (1): 59- 64.
     
  115. Duconge J, Fernandez-Sanchez E, Macias A, Castillo R, Garcia I, Beausoleil I, Amador JF, Matheu J. Monoclonal Anti EGF receptor Antibody (ior R3) Pharmacokinetic Study in Tumor Bearing Nude Mice: Role of the receptor mediated endocytosis on drug clearance. European Journal of Drug Metabolism and Pharmacokinetics. 2002; 27(2): 101-105. 
     
  116. Prats PA, Duconge J, Valenzuela C, Berlanga J, Edrosa CR, Fernandez-Sanchez E. Disposition and receptor-site binding of 125I-EGF after topical administration to skin wounds. Biopharmaceutics and Drug Disposition. 2002; 23(2): 67-76.
     
  117. Fernández-Sánchez E, Duconge J, Surroca A, Perdomo Y, González C, Bécquer MA. Estudios de Disposición Farmacocinética y Biodistribución del Anticuerpo Monoclonal ior EGF/r3 en ratas, conejos y perros. Acta Farmacéutica Bonaerense. 2002; 21(4): 245- 253.
     
  118. Prats P, Álvarez D, Torrens I, Hayes O, Zayas F, Rodríguez I, Duconge J, Fernandez-Sanchez E. Pharmacokinetic of the novel recombinant streptokinase 125I- mut C42. Biotecnología Aplicada. 2002; 19(3): 153-156.
     
  119. Perera A, Prats A, Reyes O, Bécquer M, Santiago N, Hernández A, Valdivia Y, Leyva R, Alberti L, Duconge J, Hernández F, Pimentel G, Morejón Y. El 99Tc-F11: nuevo péptico marcado para la detección gammagráfica de melanomas: resultados preclínicos. Revista Cubana de Farmacia. 2002; 36 [Suppl]: 13
     
  120. Perera A, Blanco M, Leyva R, Duconge J, Álvarez D, Fernández A, Prats A, Valdivia Y. El 99mTc- glutation como radiofármaco para el diagnóstico de tumores. Revista Cubana de Farmacia. 2002; 36 [Suppl]: 11
     
  121. Morales A, Pérez N, Núñez G, Caballero I, Duconge J, Fernández E, Veloso A, de la Paz A, Iznaga N. Freeze- dried formulation for direct 99m Tc- labeling MAb ior EGF/r3: Equivalence studies. Biotecnología Aplicada, 2000; 17: 39-44.
     
  122. Rodríguez JL, Valenzuela C, Marín N, Ferrero J, Duconge J, Castillo R, Póntigas V, Deas M, González R, López-Saura P. Comparative pharmacokinetics and pharmacodynamic of two recombinant human interferon alpha- 2b formulations administered intramuscularly in healthy male volunteers. Biotecnología Aplicada, 2000; 17: 166-170.
     
  123. Morales A, Duconge J, Álvarez D, Bécquer ML, Núñez G, Fernández E, Caballero I, Iznaga N. Humanized versus murine anti- human epidermal growth factor receptor MAb for immunoscintigraphic studies. Nuclear Medicine and Biology. 2000; 27(2): 199-206.
     
  124. Morales A, Duconge J, Caballero I, Núñez G, Fernández E, Iznaga N. Biodistribution of the 99mTc- anti-epidermal growth factor receptor humanized r3 monoclonal antibody in xenografted model of Human lung carcinoma. Nuclear Medicine and Biology. 1999; 26(3): 275-279. 
     
  125. Morales A, Núñez G, Pérez NP, Veliz BC, Caballero I, Duconge J, Fernández E, Crespo FZ, Veloso A, Iznaga N. Freeze- dried formulation for direct 99m Tc- labeling MAb ior EGF/r3: additives, biodistribution and stability. Nuclear Medicine and Biology. 1999; 26: 717-723.
     
  126. Duconge J, Prats PA, Valenzuela C, Berlanga J, Edrosa CR, Fernandez Sanchez E. Time course of 125I-recombinat human EGF in a Rat Full Thickness Skin Lesion Model. Advances in Modern Biotechnology. 1999; 5(12): 7.
     
  127. Iznaga N, Morales A, Duconge J, Torres IC, Fernández E, Gómez JA. Pharmacokinetics, Biodistribution and Dosimetry of the 99m Tc- anti-epidermal growth factor receptor humanized r3 monoclonal antibody in rats. Nuclear Medicine and Biology. 1998; 25(1): 17-23.
     
  128. Valenzuela C, Castillo R, Rodríguez JL, Marín N, Duconge J, Póntigas V, Deas M, González R, López-Saura P. Statistical Analysis on Compared Pharmacokinetics of Two Interferon Alpha-2b Formulations in Healthy Volunteers. Advances in Modern Biotechnology. 1997; 4(12): 16.
     
  129. Rodríguez JL, Valenzuela C, Marín N, Ferrero J, Duconge J, Castillo R, Póntigas V, Deas M, González R, López-Saura P. Compared Pharmacokinetics and Side Effects after a Single Intramuscular Administration of Two Interferon Alpha-2b Formulations in Healthy Volunteers. Advances in Modern Biotechnology. 1997; 4(12): 2.
     
  130. Duconge J, Montenegro A, Álvarez D, Bécquer MA, Fernández E. Estudio Comparativo de la Biodistribución en Ratas del TheraCIM  Obtenido Mediante Fermentación por Fibra Hueca y Tanque Agitado. Revista Cubana de Farmacia. 1996; 37(3): 1-7.
     
  131. Duconge J, Montenegro A, Álvarez D, Bécquer MA, Fernández E. Farmacocinética Comparada entre dos variantes de TheraCIM , en conejos F1. Revista Cubana de Farmacia. 1996; 37(3): 8-13.
     

 

Textbooks/Chapters

  1. Mariana R. Botton, Karla Claudio, Jorge Duconge, Stuart A. Scott (2019). Pharmacogenomics in Latin American Populations, Chapter 12, In: Pharmacogenomics: Challenges and Opportunities in Therapeutic Implementation. 2nd edition. Y. W. Francis Lam & Stuart A. Scott (Eds.). ISBN: 978-0-12-812626-4, Academic Press, Elsevier, Cambridge, MA, pp. 329-368. https://doi.org/10.1016/B978-0-12-812626-4.00012-7.
     
  2. Duconge J, Escalera O, Korchela M, Ruaño G. (2012). Clinical Implications of Genetic Admixture in Hispanic Puerto Ricans: Impact on the Pharmacogenetics of CYP2C19 and PON1, Chapter 7, In: Clinical Applications of Pharmacogenetics, Dr. Despina Sanoudou (Ed.), ISBN: 978-953-51-0389-9, InTech, March 21: pp. 151-164. DOI: 10.5772/28567.
     
  3. Available from: http://www.intechopen.com/books/clinical-applications-of-pharmacogenetic... RL, Duconge J, Ruaño G.  Genotype-Guided Statin Therapy. In: Pharmacogenomic Testing in Current Clinical Practice: Implementation in the Clinical Laboratory. A.H.B. Wu and K.T.J. Yeo (eds.), Molecular and Translational Medicine series. Springer Science & Business Media (Humana Press), LLC, 2011; 1st edition, Chapter 10; pp. 155-174. doi: 10.1007/978-1-60761-283-4.
     

 

Abstracts

  1. N. El Rouby, L. Marcatto, K. Claudio, L. Tavares, H. Steiner, M.R. Botton, S.A. Lubitz, S.A. Scott, J. Karnes, L.H. Cavallari, P.C.J. L. Santos, J. Duconge.  Multi-site Investigation of Pharmacogenetic Determinants of Warfarin Dose Variability in Latinos. American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics 2019, 105(S1), S119 (OIII-02).
     
  2. María del Mar Maldonado, Gabriela Rosado-González, Joseph Bloom, Linette Castillo-Pichardo, Jorge Duconge, Eliud Hernández-O'Farril, José F. Rodriguez-Orengo, Suranganie Dharmawardhane. Bioavailability and distribution of the metastatic cancer inhibitor MBQ-167 in mice. JCA-AACR, Hawai'i, Feb 2018.
     
  3. Karla Claudio-Campos, Aurora Labastida, Alga S Ramos, Andrea Gaedigk, Jessicca Y Renta, Dariana Padilla, Stuart Scott, Gualberto Ruano, Carmen Cadilla, Jorge Duconge. Genomic Association Study of Warfarin in Caribbean Hispanics. Oral-Abstract ID: 49. Tuesday, 26th June-14:05-Multi-Topics-Amphitheater, 2018 PEMED Personalized and Precision Medicine International Conference; Asiem, Paris, France, 2018. Book of Abstracts. pp. 35-36
     
  4. Maria del Mar Maldonado, Linette Castillo-Pichardo, Joseph Bloom, Jorge Duconge, José F. Rodríguez-Orengo, Eliud Hernandez-O'Farrill, Cornelis Vlaar, Suranganie Dharmawardhane. Pharmacokinetics of the metastatic cancer inhibitor MBQ-167 in mice [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018; 78(13 Suppl.): Abstract nr 4923. http://cancerres.aacrjournals.org/content/78/13_Supplement/4923.short
     
  5. Idaliz Rodríguez Escudero, Julio A Cedeño Alicea, Ileana Rodríguez Nazario, Jonathan Hernández, Jorge Duconge. Assessment of the Clinical Utility of Pharmacogenetic Testing in a Comprehensive Medication Management Service. Abstract #1992. PR Health Sci. J 2018 March; Vol. 37 No. 1 (Supplement): 44. 38th Annual Research and Education Forum. MSC UPR. Special Edition. http://prhsj.rcm.upr.edu/index.php/prhsj/issue/view/111 
     
  6. Jonnalie C Tomassini, Angélica Cuevas, Jennifer Liriano, Dariana Padilla, Nannette Rivera, Anyelis Rosario, Rocío Vega, Jessicca Renta, Héctor Núñez, Dagmar Hernández, Carmen L Cadilla, Jorge Duconge. Gene Polymorphisms linked to Clopidogrel Response within the Puerto Rican Population. Abstract #2018. PR Health Sci. J 2018 March; Vol. 37 No. 1 (Supplement): 46. 38th Annual Research and Education Forum. MSC UPR. Special Edition. http://prhsj.rcm.upr.edu/index.php/prhsj/issue/view/111
     
  7. Mery Vet George, Roberto Santiago, Jorge Duconge, Rodolfo Romañach, Torsten Stelzer. Assessment of Composite Sensor Array as Process Analytical Technology (PAT) for Quality Control of Aqueous Formulations. Abstract #2067. PR Health Sci. J 2018 March; Vol. 37 No. 1 (Supplement): 52. 38th Annual Research and Education Forum. MSC UPR. Special Edition. http://prhsj.rcm.upr.edu/index.php/prhsj/issue/view/111
     
  8. Claudio-Campos K, Orengo-Mercado C, Berrios L, Pagan R, Renta J, Cadilla C, Duconge J. CYP2C9*8 frequency distribution in Puerto Ricans: implications for warfarin dosing. The FASEB Journal 2014; vol. 28 no. 1 Supplement 1141.10
     
  9. Ramos AS, Alejandro Y, Vazquez J, Valentin I, Rivera G, Cruz I, Cadilla CL, Renta J, Duconge J. Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. A10. THSNA 2014 Summit Abstract proceedings. American Journal of Hematology. 2014; Vol. 89 (Suppl. 1): E4. DOI: 10.1002/ajh.23759
     
  10. Bermudez-Bosch LA, Rivera G, Cruz I, Felici M, Ramos A, Duconge J. A Proposal for an Individualized Pharmacogenetic-guided warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. A1. THSNA 2014 Summit Abstract proceedings. American Journal of Hematology. 2014; Vol. 89 (Suppl. 1): E1. DOI: 10.1002/ajh.23759 
     
  11. Ramos-Morales AS, Ortiz J, Alejandro Y, Valentin I, Vazquez J, Cadilla CL, Rivera G, Duconge J. Role of Admixture in a Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. PR Health Sci J. Abstract XXXIV Annual Research and Education Forum MSC. March 2014; 33 (suppl. 1): 41, A-108.
     
  12. Claudio-Campos K, Orengo C, Berrios L, Pagan R, Renta J, Cadilla C, Duconge J. CYP2C9*8 frequency distribution in Puerto Ricans: Implications for warfarin dosing. PR Health Sci J. Abstract XXXIV Annual Research and Education Forum MSC. March 2014; 33 (suppl. 1): 102, A-283.
     
  13. Bermúdez-Bosch LA, Rivera-Miranda G, Cruz I, Felici M, Ramos AS, Duconge J. A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy. PR Health Sci J. Abstract XXXIV Annual Research and Education Forum MSC. March 2014; 33 (suppl. 1): 108, A-298.
     
  14. Ramos AS, Alejandro-Cowan Y, Vazquez J, Valentin I, Rivera G, Renta J, Cruz I, Feliu JF, Cadilla CL, Seip R, Ruaño G, Duconge J. Pharmacogenetic-driven warfarin dosing algorithm in Puerto Rican patients. In: Warfarin Dosing Management/ Abstract J3. Special Issue: Proceedings of the 12th National Conference on Anticoagulant Therapy. J Thrombosis and Thrombolysis. 2013; 35(3): 417
     
  15. Valentin II, Rivera G, Nieves M, Vazquez J, Cruz I, Renta J, Feliu JF, Cadilla CL, Duconge J. A Pharmacogenetic Safety Profile of Puerto Ricans on Warfarin Therapy. A10. THSNA meeting proceedings. American Journal of Hematology. 2012; Vol. 87 (Suppl. 1): S152. 
     
  16. Ramos AS, Rivera G, García R, Alejandro Y, Cruz I, Renta J, Feliu JF, Cadilla CL, Seip R, Ruaño G, Duconge J. Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. A11. THSNA meeting proceedings. American Journal of Hematology. 2012; Vol. 87 (Suppl. 1): S152-53.
     
  17. Ortiz-Melendez C, Duconge J. Prevalence of Polymorphic CYP2D6 alleles in Puerto Ricans: preliminary results. Abstract XXX Annual Research and Education Forum. PR Health Sci J 2010; 29(2): 157-R062.
     
  18. Vazquez J, Valentin II, Rivera G, Seip R, Renta JY, Korchela M, Bogaard K, Cruz I, Cadilla CL, Duconge J. Pharmacogenetic-driven Warfarin Dosing Algorithm in Puerto Ricans. Abstract XXX Annual Research and Education Forum. PR Health Sci J 2010; 29(2): 168-R099.
     
  19. Lojo L, Duconge J, Santiago-Borrero PJ. Integrating Combinatorial CYP2C9 and VKORC1 Genotypes into Clinical Warfarin Management in Puerto Rican Children with Thrombosis: An Illustrative Cases Study. American Society of Pediatric Hematology/Oncology 23rd Annual Meeting: Abstracts (Special Issue). Pediatric Blood & Cancer 2010; 54(6): 811-P162
     
  20. Bilbao M, Peña Y, Cabrera MA, Duconge J. Análisis diferencial de las potencialidades de promoción de absorción de una familia de 1-O-alquil gliceroles. Revista Cubana de Farmacia. 2005; 38 [Suppl]: 12.
     
  21. Aguilera A, Duconge J, Valenzuela C, Alfonso Z. Evaluación del efecto del factor de crecimiento epidérmico humano recombinante en formulaciones semisólidas. Revista Cubana de Farmacia. 2005; 38 [Suppl]: 8
     
  22. Fernández E, Torres M, Duconge J, Bécquer MA, Álvarez D. Paradigma alométrico en farmacocinética: ¿Realidad o quimera? Revista Cubana de Farmacia. 2005; 38 [Suppl]: